In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Serono, ZymoGenetics to develop proteins

Executive Summary

In a deal that grew out of their 2001 collaboration on autoimmune therapeutics, Serono SA has licensed exclusive worldwide rights to three of ZymoGenetics's preclinical proteins: fibroblast growth factor 18 (FGF-18, for treating cartilage damaged by osteoarthritis or physical injury), interleukin 22 receptor (IL-22R, psoriasis), and interleukin 31 (IL-31, an anti-inflammatory for asthma, IBD, psoriasis, and potentially atopic dermatitis; ZG retains co-development and co-commercialization rights in the US for this one). For these projects, Serono will pay $11.25mm in up-front licensing fees, plus milestones that could exceed $100mm.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies